Highlighting that the insulin market currently has just a handful of players and provides huge scope for growth, Kiran Mazumdar Shaw, CMD of Biocon says, the company will be filing its first insulin analogue dossier in FY17.
first published: Mar 17, 2016 10:00 am
A collection of the most-viewed Moneycontrol videos.
This Tenant Moved from a 100sqft Slum to a Premium Residence | The Tenant
Live: Nifty snaps 4-day winning streak but rises 1% this week | Closing Bell
Live: Can Bihar poll outcome trigger Nifty to reclaim 26,000-mark? | Opening Bell
Live: Nifty holds above 25,900 but off nearly 100 pts from day's high | Closing Bell
